Cargando…

Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma

BACKGROUND: CD86 has great potential to be a new target of immunotherapy by regulating cancer immune response. However, it remains unclear whether CD86 is a friend or foe in lower-grade glioma (LGG). METHODS: The prognostic value of CD86 expression in pan-cancer was analyzed using Cox regression and...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Huaide, Tian, Wei, He, Yikang, Li, Jiahui, He, Chuan, Li, Yongqiang, Liu, Ning, Li, Jianan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089378/
https://www.ncbi.nlm.nih.gov/pubmed/33954112
http://dx.doi.org/10.3389/fonc.2021.654350
_version_ 1783687034084261888
author Qiu, Huaide
Tian, Wei
He, Yikang
Li, Jiahui
He, Chuan
Li, Yongqiang
Liu, Ning
Li, Jianan
author_facet Qiu, Huaide
Tian, Wei
He, Yikang
Li, Jiahui
He, Chuan
Li, Yongqiang
Liu, Ning
Li, Jianan
author_sort Qiu, Huaide
collection PubMed
description BACKGROUND: CD86 has great potential to be a new target of immunotherapy by regulating cancer immune response. However, it remains unclear whether CD86 is a friend or foe in lower-grade glioma (LGG). METHODS: The prognostic value of CD86 expression in pan-cancer was analyzed using Cox regression and Kaplan-Meier analysis with data from the cancer genome atlas (TCGA). Cancer types where CD86 showed prognostic value in overall survival and disease-specific survival were identified for further analyses. The Chinese Glioma Genome Atlas (CGGA) dataset were utilized for external validation. Quantitative real-time PCR (qRT-PCR), Western blot (WB), and Immunohistochemistry (IHC) were conducted for further validation using surgical samples from Jiangsu Province hospital. The correlations between CD86 expression and tumor immunity were analyzed using the Estimation of Stromal and Immune cells in Malignant Tumours using Expression data (ESTIMATE) algorithm, Tumor IMmune Estimation Resource (TIMER) database, and expressions of immune checkpoint molecules. Gene Set Enrichment Analysis (GSEA) was performed using clusterprofiler r package to reveal potential pathways. RESULTS: Pan-cancer survival analysis established CD86 expression as an unfavorable prognostic factor in tumor progression and survival for LGG. CD86 expression between Grade-II and Grade-III LGG was validated using qRT-PCR and WB. Additionally, CD86 expression in LGG with unmethylated O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter was significantly higher than those with methylated MGMT (P<0.05), while in LGG with codeletion of 1p/19q it was significantly downregulated as opposed to those with non-codeletion (P<2.2*10-16). IHC staining validated that CD86 expression was correlated with MGMT status and X1p/19q subtypes, which was independent of tumor grade. Multivariate regression validated that CD86 expression acts as an unfavorable prognostic factor independent of clinicopathological factors in overall survival of LGG patients. Analysis of tumor immunity and GSEA revealed pivotal role of CD86 in immune response for LGG. CONCLUSIONS: Integrated analysis shows that CD86 is an unfavorable prognostic biomarker in LGG patients. Targeting CD86 may become a novel approach for immunotherapy of LGG.
format Online
Article
Text
id pubmed-8089378
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80893782021-05-04 Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma Qiu, Huaide Tian, Wei He, Yikang Li, Jiahui He, Chuan Li, Yongqiang Liu, Ning Li, Jianan Front Oncol Oncology BACKGROUND: CD86 has great potential to be a new target of immunotherapy by regulating cancer immune response. However, it remains unclear whether CD86 is a friend or foe in lower-grade glioma (LGG). METHODS: The prognostic value of CD86 expression in pan-cancer was analyzed using Cox regression and Kaplan-Meier analysis with data from the cancer genome atlas (TCGA). Cancer types where CD86 showed prognostic value in overall survival and disease-specific survival were identified for further analyses. The Chinese Glioma Genome Atlas (CGGA) dataset were utilized for external validation. Quantitative real-time PCR (qRT-PCR), Western blot (WB), and Immunohistochemistry (IHC) were conducted for further validation using surgical samples from Jiangsu Province hospital. The correlations between CD86 expression and tumor immunity were analyzed using the Estimation of Stromal and Immune cells in Malignant Tumours using Expression data (ESTIMATE) algorithm, Tumor IMmune Estimation Resource (TIMER) database, and expressions of immune checkpoint molecules. Gene Set Enrichment Analysis (GSEA) was performed using clusterprofiler r package to reveal potential pathways. RESULTS: Pan-cancer survival analysis established CD86 expression as an unfavorable prognostic factor in tumor progression and survival for LGG. CD86 expression between Grade-II and Grade-III LGG was validated using qRT-PCR and WB. Additionally, CD86 expression in LGG with unmethylated O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter was significantly higher than those with methylated MGMT (P<0.05), while in LGG with codeletion of 1p/19q it was significantly downregulated as opposed to those with non-codeletion (P<2.2*10-16). IHC staining validated that CD86 expression was correlated with MGMT status and X1p/19q subtypes, which was independent of tumor grade. Multivariate regression validated that CD86 expression acts as an unfavorable prognostic factor independent of clinicopathological factors in overall survival of LGG patients. Analysis of tumor immunity and GSEA revealed pivotal role of CD86 in immune response for LGG. CONCLUSIONS: Integrated analysis shows that CD86 is an unfavorable prognostic biomarker in LGG patients. Targeting CD86 may become a novel approach for immunotherapy of LGG. Frontiers Media S.A. 2021-04-19 /pmc/articles/PMC8089378/ /pubmed/33954112 http://dx.doi.org/10.3389/fonc.2021.654350 Text en Copyright © 2021 Qiu, Tian, He, Li, He, Li, Liu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qiu, Huaide
Tian, Wei
He, Yikang
Li, Jiahui
He, Chuan
Li, Yongqiang
Liu, Ning
Li, Jianan
Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma
title Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma
title_full Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma
title_fullStr Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma
title_full_unstemmed Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma
title_short Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma
title_sort integrated analysis reveals prognostic value and immune correlates of cd86 expression in lower grade glioma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089378/
https://www.ncbi.nlm.nih.gov/pubmed/33954112
http://dx.doi.org/10.3389/fonc.2021.654350
work_keys_str_mv AT qiuhuaide integratedanalysisrevealsprognosticvalueandimmunecorrelatesofcd86expressioninlowergradeglioma
AT tianwei integratedanalysisrevealsprognosticvalueandimmunecorrelatesofcd86expressioninlowergradeglioma
AT heyikang integratedanalysisrevealsprognosticvalueandimmunecorrelatesofcd86expressioninlowergradeglioma
AT lijiahui integratedanalysisrevealsprognosticvalueandimmunecorrelatesofcd86expressioninlowergradeglioma
AT hechuan integratedanalysisrevealsprognosticvalueandimmunecorrelatesofcd86expressioninlowergradeglioma
AT liyongqiang integratedanalysisrevealsprognosticvalueandimmunecorrelatesofcd86expressioninlowergradeglioma
AT liuning integratedanalysisrevealsprognosticvalueandimmunecorrelatesofcd86expressioninlowergradeglioma
AT lijianan integratedanalysisrevealsprognosticvalueandimmunecorrelatesofcd86expressioninlowergradeglioma